Skip to main
  1. Stocks
  2. CRISPR Therapeutics
  3. Forecast
CRSP

CRISPR Therapeutics (CRSP) Stock Forecast & Price Target

CRISPR Therapeutics (CRSP) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 27%
Hold 36%
Sell 0%
Strong Sell 0%

Bulls say

CRISPR Therapeutics is supported by accelerating Casgevy momentum, with 3Q:26 sales of $99.2M topping Street estimates and infusions through 3Q:26 doubling FY:25 levels, reinforcing confidence that reimbursement, penetration, and the pediatric label expansion can drive continued growth. Beyond the commercial launch, CTX310 has shown durable one-year reductions in ANGPTL3, LDL-C, and triglycerides with favorable safety, strengthening the case for a potentially differentiated one-time cardiovascular therapy. The balance sheet and pipeline also support the outlook, with about $2.2B in estimated YE:26 cash and multiple clinical assets advancing in immuno-oncology, cardiovascular disease, and Type 1 diabetes.

Bears say

CRISPR Therapeutics is viewed negatively because the bull case depends heavily on Casgevy, yet sales may fail to accelerate and several earlier-stage programs could be discontinued, which would pressure valuation and reduce future growth optionality. The company also faces substantial development risk across exa-cel, CTX112, CTX310, CTX340, CTX460, and CTX611, including uncertainty around safety, efficacy, and durability in clinical trials, all of which is amplified by the novelty of gene editing. On top of that, commercialization is challenged by competing programs in beta thalassemia, sickle cell disease, and CD19 oncology, while unresolved intellectual property issues and manufacturing, legal, regulatory, and financial risks further weaken the investment case.

CRISPR Therapeutics (CRSP) has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 27% recommend Buy, 36% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CRISPR Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

CRISPR Therapeutics (CRSP) Analyst Forecast & Price Prediction

Get the latest CRISPR Therapeutics (CRSP) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in CRISPR Therapeutics (CRSP)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CRISPR Therapeutics (CRSP) Forecast

Analysts have given CRISPR Therapeutics (CRSP) a Buy based on their latest research and market trends.

According to 11 analysts, CRISPR Therapeutics (CRSP) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $74.09, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $74.09, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CRISPR Therapeutics (CRSP)


CRISPR Therapeutics (CRSP) Analyst Forecast & Price Prediction

Get the latest CRISPR Therapeutics (CRSP) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in CRISPR Therapeutics (CRSP)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover CRSP stock data and trends